[18F]JNJ42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP.
Phosphodiesterase 10A (PDE10A) is a key regulator of medium spiny neuron excitability. Therefore, it plays an important role in the regulation of motor, reward, and cognitive processes. Despite the interest in PDE10A as a drug and positron emission tomography (PET) imaging target, little is known about the regulation of PDE10A enzymatic activity. This study aimed to further investigate the role of cAMP in the regulation of PDE10A activity and PDE10A PET imaging. Using [18F]JNJ42259152 as radioligand, we investigated alterations in PDE10A binding secondary to changes in cAMP levels. An in vitro striatum homogenate binding assay was developed to determine KDand Bmaxof [18F]JNJ42259152. Homogenate binding was assessed after addition of increasing concentrations of exogenous cAMP (1, 10, and 100 μM). Rats were treated using JNJ49137530 and rolipram to induce in vivo alterations of cAMP. The effect of the induced cAMP alterations on PDE10A binding was assessed by comparing [18F]JNJ42259152 microPET studies after treatment to microPET studies acquired at baseline conditions prior to treatment. In vitro binding affinity of [18F]JNJ42259152 was higher in the presence of cAMP compared to baseline conditions (KD= 3.17 ± 0.91 nM with 10 μM cAMP vs. KD= 6.62 ± 0.7 nM at baseline). Inhibition of PDE4 using rolipram significantly increased [18F]JNJ42259152 binding (BPND= 2.61 ± 0.50 vs. 1.91 ± 0.36 at baseline). Administration of the PDE2 inhibitor JNJ49137530 significantly increased PDE10A binding potential (BPND= 2.74 ± 0.22 vs. 2.05 ± 0.16 at baseline). Our data indicate an important role for cAMP in the regulation of PDE10A activity. Additionally, our data show a profound interaction between several PDEs in striatum.
Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences KU Leuven, Leuven, Belgium.
Maarten
M
Ooms
Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences KU Leuven, Leuven, Belgium.
Bala
B
Attili
Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences KU Leuven, Leuven, Belgium.
Sofie
S
Celen
Division of Nuclear Medicine, KU Leuven and University Hospital Leuven, Leuven, Belgium.
Michel
M
Koole
Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences KU Leuven, Leuven, Belgium.
Alfons
A
Verbruggen
Division of Nuclear Medicine, KU Leuven and University Hospital Leuven, Leuven, Belgium.
Koen
K
Van Laere
Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences KU Leuven, Leuven, Belgium.
Guy
G
Bormans
D000818:Animals; D000242:Cyclic AMP / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005462:Fluorine Radioisotopes / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D011485:Protein Binding / Q000502:physiology; D011720:Pyrazoles / Q000378:metabolism*; D011725:Pyridines / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar
C581925:2-((4-(1-(2-fluoroethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)phenoxy)methyl)-3,5-dimethylpyridine; D005462:Fluorine Radioisotopes; D011720:Pyrazoles; D011725:Pyridines; D000242:Cyclic AMP; C512064:PDE10A protein, rat; D010727:Phosphoric Diester Hydrolases
[18F]JNJ42259152; brain imaging; cyclic AMP; phosphodiesterase 10A; small animal PET